Literature DB >> 12404680

Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes.

Kristian Linnet1.   

Abstract

Olanzapine is a widely used, newer antipsychotic agent, which is metabolized by various pathways: hydroxylation and N-demethylation by cytochrome P450, N-oxidation by flavin monooxygenase and direct glucuronidation. In vivo studies have pointed towards the latter pathway as being of major importance. Accordingly, the glucuronidation reaction was studied in vitro using cDNA-expressed human UDP-glucuronosyltransferase (UGT) enzymes and a pooled human liver microsomal preparation (HLM). Glucuronidated olanzapine was determined by HPLC after acid or enzymatic hydrolysis. The following UGT-isoenzymes were screened for their ability to glucuronidate olanzapine: 1A1, 1A3, 1A4, 1A6, 1A9, 2B7 and 2B15. Only UGT1A4 was able to glucuronidate olanzapine obeying saturation kinetics. The K(m) value was 227 micromol/l (SE 43), i.e. of the same order of magnitude as for other psychotropic drugs, and the V(max) value was 2370 pmol/(min mg) (SE 170). Glucuronidation was also mediated by the HLM preparation, but a saturation level was not reached. The olanzapine glucuronidation reaction was inhibited by several drugs known as substrates for UGT1A4, e.g. amitriptyline, trifluoperazine and lamotrigine. Thus, competition for glucuronidation by UGT1A4 represents a possibility for drug-drug interactions in subjects receiving several of these psychotropic drugs at the same time. Whether such possible interactions are of any clinical importance may await further studies in patients. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404680     DOI: 10.1002/hup.403

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  17 in total

1.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

2.  The presynaptic component of the serotonergic system is required for clozapine's efficacy.

Authors:  Prem N Yadav; Atheir I Abbas; Martilias S Farrell; Vincent Setola; Noah Sciaky; Xi-Ping Huang; Wesley K Kroeze; LaTasha K Crawford; David A Piel; Michael J Keiser; John J Irwin; Brian K Shoichet; Evan S Deneris; Jay Gingrich; Sheryl G Beck; Bryan L Roth
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

3.  The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.

Authors:  Simon J C Davies; Benoit H Mulsant; Alastair J Flint; Barnett S Meyers; Anthony J Rothschild; Ellen M Whyte; Margaret M Kirshner; Denise Sorisio; Bruce G Pollock; Robert R Bies
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

4.  Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.

Authors:  Roza Ghotbi; Buster Mannheimer; Eleni Aklillu; Akira Suda; Leif Bertilsson; Erik Eliasson; Urban Osby
Journal:  Eur J Clin Pharmacol       Date:  2010-02-09       Impact factor: 2.953

Review 5.  Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 6.  Nuclear receptor PXR, transcriptional circuits and metabolic relevance.

Authors:  Chibueze A Ihunnah; Mengxi Jiang; Wen Xie
Journal:  Biochim Biophys Acta       Date:  2011-02-02

Review 7.  Interactions between antiepileptic and antipsychotic drugs.

Authors:  Frank M C Besag; David Berry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.

Authors:  Korbtham Sathirakul; Clark Chan; Leyan Teng; Richard F Bergstrom; Kwee Poo Yeo; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

9.  Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.

Authors:  Jagdev Sidhu; Sarah Job; Jonathan Bullman; Emma Francis; Richard Abbott; John Ascher; Jochen G W Theis
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

Review 10.  Clinical applications of CYP genotyping in psychiatry.

Authors:  Edoardo Spina; Jose de Leon
Journal:  J Neural Transm (Vienna)       Date:  2014-09-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.